You just read:

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

News provided by

AbbVie

Jun 12, 2018, 06:38 ET